Preoperative oncologic therapy and the prolonged risk of venous thromboembolism in resectable pancreatic cancer.
long-term effects
neoadjuvant therapy
pancreatic neoplasms
pancreaticoduodenectomy
preoperative chemoradiation
venous thrombosis
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
revised:
24
09
2021
received:
26
07
2021
accepted:
19
10
2021
pubmed:
12
2
2022
medline:
9
4
2022
entrez:
11
2
2022
Statut:
ppublish
Résumé
Pancreatic cancer is one of the most prothrombotic cancers. Among patients receiving preoperative chemotherapy followed by surgery, chemotherapy and surgery represent a compound risk for venous thromboembolism (VTE), rendering the postoperative time a period of interest. We aimed to analyze whether preoperative oncologic therapy increases the risk for VTE after surgery and identify which characteristics associate with VTE. We first identified patients surgically treated for pancreatic cancer at Helsinki University Hospital between 2000 and 2017, collecting the following data: gender, age at surgery, preoperative medication, body mass index (BMI), preoperative chemo(radio)therapy, tumor size, positive node ratio, perineural and perivascular invasion, tumor grade, surgical technique, postoperative anticoagulation, adjuvant therapy, time of VTE, time of local disease recurrence, time of distant metastasis, and time of death. With a follow-up period of at least 2 years or until death, we compared a total of 93 preoperative oncologic therapy and 291 upfront surgery patients (n = 384, median age 66.5 years). Preoperative oncologic therapy increased the risk for thrombosis after surgery (hazard ratio [HR] 1.61; 95% confidence interval [CI] 1.03-2.53). The VTE incidence rate remained high for up to 2 years after surgery. BMI ≥30 kg/m Preoperative oncologic therapy represents an independent risk factor for VTE, not only during the immediate postoperative period but up to 2 years after surgery. VTE is associated with obesity, prior anticoagulation, and disease recurrence and diminishes overall survival.
Sections du résumé
BACKGROUND
Pancreatic cancer is one of the most prothrombotic cancers. Among patients receiving preoperative chemotherapy followed by surgery, chemotherapy and surgery represent a compound risk for venous thromboembolism (VTE), rendering the postoperative time a period of interest. We aimed to analyze whether preoperative oncologic therapy increases the risk for VTE after surgery and identify which characteristics associate with VTE.
METHODS
We first identified patients surgically treated for pancreatic cancer at Helsinki University Hospital between 2000 and 2017, collecting the following data: gender, age at surgery, preoperative medication, body mass index (BMI), preoperative chemo(radio)therapy, tumor size, positive node ratio, perineural and perivascular invasion, tumor grade, surgical technique, postoperative anticoagulation, adjuvant therapy, time of VTE, time of local disease recurrence, time of distant metastasis, and time of death. With a follow-up period of at least 2 years or until death, we compared a total of 93 preoperative oncologic therapy and 291 upfront surgery patients (n = 384, median age 66.5 years).
RESULTS
Preoperative oncologic therapy increased the risk for thrombosis after surgery (hazard ratio [HR] 1.61; 95% confidence interval [CI] 1.03-2.53). The VTE incidence rate remained high for up to 2 years after surgery. BMI ≥30 kg/m
CONCLUSIONS
Preoperative oncologic therapy represents an independent risk factor for VTE, not only during the immediate postoperative period but up to 2 years after surgery. VTE is associated with obesity, prior anticoagulation, and disease recurrence and diminishes overall survival.
Identifiants
pubmed: 35148464
doi: 10.1002/cam4.4397
pmc: PMC8986147
doi:
Substances chimiques
Anticoagulants
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1605-1616Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
J Oncol Pharm Pract. 2019 Jun;25(4):818-823
pubmed: 29540105
Thromb Res. 2018 Apr;164 Suppl 1:S112-S118
pubmed: 29703467
Lancet. 2000 Apr 15;355(9212):1295-302
pubmed: 10776741
J Clin Oncol. 2009 Oct 10;27(29):4839-47
pubmed: 19720906
Arch Intern Med. 1998 Mar 23;158(6):585-93
pubmed: 9521222
JAMA Intern Med. 2015 Sep;175(9):1474-80
pubmed: 26168152
Cancer. 2007 Nov 15;110(10):2339-46
pubmed: 17918266
Ann Surg Oncol. 2019 May;26(5):1503-1511
pubmed: 30652227
Sci Rep. 2020 Jan 28;10(1):1332
pubmed: 31992753
Open Cardiovasc Med J. 2010 Feb 23;4:78-82
pubmed: 20360976
Clin Cancer Res. 2005 Apr 1;11(7):2531-9
pubmed: 15814630
PLoS Med. 2012;9(7):e1001275
pubmed: 22859911
Cancer Med. 2022 Apr;11(7):1605-1616
pubmed: 35148464
Arterioscler Thromb Vasc Biol. 2009 Dec;29(12):2176-81
pubmed: 19778945
World J Gastroenterol. 2006 Aug 14;12(30):4843-9
pubmed: 16937466
Blood. 2008 May 15;111(10):4902-7
pubmed: 18216292
Oncotarget. 2018 May 29;9(41):26453-26465
pubmed: 29899870
Lancet Oncol. 2005 Jun;6(6):401-10
pubmed: 15925818
Blood. 2013 Sep 12;122(11):1873-80
pubmed: 23798713
Br J Cancer. 2010 Sep 28;103(7):947-53
pubmed: 20842120
Clin Appl Thromb Hemost. 2018 Nov;24(8):1267-1275
pubmed: 29865859
Hematology Am Soc Hematol Educ Program. 2013;2013:684-91
pubmed: 24319253
Scand J Surg. 2017 Mar;106(1):54-61
pubmed: 27130378
Semin Thromb Hemost. 2019 Jun;45(4):385-395
pubmed: 31096306
Thromb Res. 2010 Apr;125 Suppl 2:S1-7
pubmed: 20433985
Res Pract Thromb Haemost. 2017 May 25;1(1):112-119
pubmed: 30046679
J Am Coll Surg. 2021 Apr;232(4):405-413
pubmed: 33338577
Cancer. 2013 Feb 1;119(3):648-55
pubmed: 22893596
JAMA. 2004 Oct 20;292(15):1867-74
pubmed: 15494585
Haematologica. 2013 Aug;98(8):1309-14
pubmed: 23585523
Gastroenterology. 2020 Apr;158(5):1346-1358.e4
pubmed: 31843588
Oncologist. 2017 Feb;22(2):199-207
pubmed: 28174293
Br J Cancer. 2010 Apr 13;102 Suppl 1:S2-9
pubmed: 20386546
JAMA. 2005 Feb 9;293(6):715-22
pubmed: 15701913
J Thromb Haemost. 2005 Dec;3(12):2664-70
pubmed: 16359505
Ann Surg. 2006 Jan;243(1):89-95
pubmed: 16371741
Blood. 2017 Sep 28;130(13):1499-1506
pubmed: 28807983
N Engl J Med. 2005 Dec 1;353(22):2373-83
pubmed: 16319386
Br J Haematol. 2008 Mar;140(5):488-95
pubmed: 18275426
Clin Cancer Res. 2007 May 15;13(10):2870-5
pubmed: 17504985
Chest. 2008 Jun;133(6 Suppl):381S-453S
pubmed: 18574271
J Surg Oncol. 2016 Oct;114(5):581-586
pubmed: 27760280
Scand J Gastroenterol. 2006 Sep;41(9):1095-104
pubmed: 16938724
Thromb Res. 2020 Jan;185:125-131
pubmed: 31812026
J Thromb Haemost. 2011 Jul;9 Suppl 1:316-24
pubmed: 21781268
Acta Oncol. 2020 Feb;59(2):237-241
pubmed: 31650877
Dis Mon. 2016 May;62(5):121-58
pubmed: 27037224